IP Library Granted Patent US 12686704
Granted Patent B2
US 12686704 · App. 18/287,276 · Granted Jul 21, 2026

Procoagulant peptides and use thereof

Inventor: Yona Nadir (Zichron Yaakov, IL)
Assignee: RAMBAM MED-TECH LTD.
C07K14/001A61L15/32A61P7/04C07K4/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12686704
App. No.
18/287,276
Granted
Jul 21, 2026
Kind
B2
Abstract

There is provided procoagulant peptides, and use of same, such as in treatment of hemostasis-related diseases or disorders, and/or wound healing.

Claims (8)

1 . A peptide consisting of the amino acid sequence GSKRRKLRVYLHCT (SEQ ID NO: 2), wherein the N-terminus is acetylated and the C-terminus is amidated.

2 . A pharmaceutical composition comprising the peptide of claim 1 , and a pharmaceutically acceptable carrier.

3 . A wound dressing comprising the peptide of claim 1 .

4 . A method for treating a subject in need of wound healing, the method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a procoagulant peptide consisting of the amino acid sequence GSKRRKLRVYLHCT (SEQ ID NO: 2), wherein the N-terminus is acetylated and the C-terminus is amidated, thereby treating the subject in need of wound healing.

5 . A method for treating a subject in need of induction of coagulation, the method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a procoagulant peptide consisting of the amino acid sequence GSKRRKLRVYLHCT (SEQ ID NO: 2), wherein the N-terminus is acetylated and the C-terminus is amidated, thereby treating the subject in need of induction of coagulation.

6 . The method of claim 5 , wherein said subject is afflicted with a wound, hemorrhage, or both.

7 . The method of claim 5 , wherein said subject is afflicted with a disease or a disorder being selected from the group consisting of: hemostatic disorder, anticoagulation disorder, angiogenesis-related disease, hemophilia, and any combination thereof.

8 . The method of claim 5 , wherein said administering comprises: subcutaneously administering, intravenously administering, topically administering, or any combination thereof.